Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CorMedix Inc. (CRMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.8300+0.0100 (+0.35%)
At close: 04:00PM EDT
2.8300 0.00 (0.00%)
After hours: 05:06PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference

    BERKELEY HEIGHTS, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that management will be presenting a corporate overview at the H.C. Wainwright Annual Global Investment Conference being held in New York on September 12 – 14, 2022. H.C. Wainwright Annual Global Investment Conference Date: Monday,

  • GlobeNewswire

    CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update

    Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the second quarter and six months ended June 30, 2022 and provided an update on recent business events. Recent Corporate Highlights: CorMedix announc

  • Benzinga

    CorMedix Slapped With Second FDA Rejection For DefenCath

    CorMedix Inc (NASDAQ: CRMD) received a second Complete Response Letter (CRL) from the FDA for DefenCath, developed as a catheter lock solution to reduce catheter-related bloodstream infections in patients with renal failure receiving chronic hemodialysis via a central venous catheter. The letter states that DefenCath cannot be approved until deficiencies recently conveyed to the contract manufacturing organization and the supplier of the active pharmaceutical ingredient heparin during inspection

Advertisement
Advertisement